Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience.
Vincent MarmousetJustine DecroocqSylvain GarciazGabriel EtienneAmine BelhabriSarah BertoliLauris GastaudCélestine SimandSylvain P ChantepieMadalina UzunovAlexis GenthonCeline BerthonEdmond ChichePierre-Yves DumasJacques VargaftigGéraldine SalmeronEmilie LemasleEmmanuelle TavernierJérémy DelageMarion LoiratNadine MorineauFélix Blanc-DurandPatricia PautierVéronique VergéNathalie AugerMyrtille ThomasLaetitia StefaniMarion LepelleyThomas BoyerSylvain ThépotMarie-Pierre GourinPascal BourquardMatthieu DuchmannPierre-Marie MoriceMauricette MichalletLionel AdesPierre FenauxChristian RecherHervé DombretArnaud PagèsChristophe MarzacAlexandra LearyJean-Baptiste Micolnull nullPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
In a large series, we described a high incidence of t-MN post-PARPi associated with unfavorable cytogenetic and molecular abnormalities leading to poor OS. Early detection is crucial, particularly in cases of delayed cytopenia.